These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31788837)

  • 1. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
    Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
    Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
    Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
    Kobayashi T; Iwama S; Yamagami A; Izuchi T; Suzuki K; Otake K; Yasuda Y; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Nishio N; Mori S; Shimokata T; Sano T; Niimi K; Yoshikawa N; Akamatsu S; Ando Y; Akiyama M; Sone M; Ishii M; Arima H
    Cancer Immunol Immunother; 2024 Jun; 73(8):146. PubMed ID: 38833157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
    Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
    J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
    Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
    Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 13. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
    Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
    Morganstein DL; Lai Z; Spain L; Diem S; Levine D; Mace C; Gore M; Larkin J
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):614-620. PubMed ID: 28028828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
    Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
    Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.